Caribou Biosciences Inc Earnings

The next earnings date for Caribou Biosciences Inc is May 12, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Caribou Biosciences Inc Earnings

Report Date	Estimated Earnings Per Share
05/12/2026	$-0.33

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Caribou Biosciences Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
03/16/2026	---	$-0.28	13.29%
11/11/2025	---	$0	100.00%
08/12/2025	---	$-0.35	9.09%
05/09/2025	---	$-0.44	2.22%
11/07/2024	---	$-0.38	15.11%
08/07/2024	---	$-0.44	0.91%
05/07/2024	---	$-0.46	-12.06%
03/11/2024	After Market	$-0.39	-5.41%
11/07/2023	After Market	$-0.12	71.43%
08/08/2023	After Market	$-0.48	2.04%
05/09/2023	After Market	$-0.46	6.12%
03/09/2023	After Market	$-0.44	4.35%
11/08/2022	After Market	$-0.44	8.33%
08/09/2022	After Market	$-0.44	-22.22%
05/09/2022	After Market	$-0.32	8.57%
03/21/2022	After Market	$-0.31	13.89%
11/09/2021	After Market	$-0.46	-283.33%
09/02/2021	After Market	$-1.55	-469.05%
06/02/2021	---	$-0.93	---
03/31/2021	---	$-1.39	---
03/31/2020	---	$-1.16	---

More About Caribou Biosciences Inc

Website

https://cariboubio.com

Country

USA

Full Time Employees

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

“Caribou Biosciences Inc Earnings” Can Refer to the Caribou Biosciences Inc Earnings Date

Some people say “Caribou Biosciences Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Caribou Biosciences Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Caribou Biosciences Inc Stock on the Earnings Date

If you own Caribou Biosciences Inc stock (CRBU) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Caribou Biosciences Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Caribou Biosciences Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Caribou Biosciences Inc Earnings

You can contact us any time if you would like to ask questions about Caribou Biosciences Inc earnings or anything else related to the stock market.